Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NeuroTherm buys S&N interventional spine pain management biz

This article was originally published in The Gray Sheet

Executive Summary

NeuroTherm acquires Smith & Nephew's interventional spine pain management business, the firm announces April 7. The deal will "go a long way towards sustaining NeuroTherm's leading position in the interventional pain space," an estimated $5 billion global market, according to CEO Larry Hicks. Headquartered in Wilmington, Mass., NeuroTherm gains S&N's CDS Discography System, Spinecath and Acutherm catheters, and a line of radiofrequency devices. It also will be a distributor of the Trucath injection system. NeuroTherm's existing lineup includes RF devices and catheters for pain. The acquired product line "is highly complementary," the firm notes

You may also be interested in...



'Purple Drank' Drug Cocktail Linked To France's Latest Reverse-Switch

Promethazine has been reverse-switched from OTC to prescription status in France, with rising abuse of the drug in the so-called Purple Drank cocktail one of the motivating factors for the move by the country's health ministry.

P&G Causes Friction With UK Cosmetics Firm Over Ad Claim

Can shaving ever be “friction free”? Not according to Procter & Gamble, which challenged in a complaint to the UK Advertising Standards Authority a claim made by a British cosmetics firm FFS that it provided a “friction free” shaving experience for women via its subscription razor service.

UK Readies Medtech And Pharma Sectors For Regulatory Life Outside The EU

Work has started on UK-only regulations for the medtech and medicines sectors, to ensure that the regulatory framework not only functions but can also react swiftly to needs after the UK leaves the EU. This article is part two of two.

Topics

UsernamePublicRestriction

Register

MT028732

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel